Serum microRNA expression levels in Turkish patients with Parkinson’s disease
Objective: To determine the serum expression levels of miR-19a, miR-19b, miR-29a, miR-29c, miR-181, miR-195 and miR-221 in Turkish patients with Parkinson's disease (PD) and to…Comparison of gait measures in a clinic and a community setting in people with and without Parkinson’s disease
Objective: This study aimed to investigate measures that best discriminated gait characteristics of people with Parkinson's disease (PD) from age-matched healthy control subjects (HC) in…On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups
Objective: To quantify preference heterogeneity for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD commonly experience “OFF” episodes.…Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Evidence towards the clinical benefits of using directional leads in Deep Brain Stimulation for movement disorders: Consecutive case series
Objective: The objective of the present study was determinate the clinical benefits using directional leads in DBS in two different centers. Background: Deep brain stimulation…Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease
Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare
Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD) receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients
Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort
Objective: The goal of this study is to describe the factors that may have an impact on Continuous Subcutaneous Apomorphine Infusion (CSAI) therapy initiation and…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 149
- Next Page »